PALO ALTO, Calif., March 27, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the fourth quarter and full year ended ...

Also, this fund has significantly underperformed COIN's upwards appreciation, while only slightly outperforming the company during the recent sell-off. The income CONY pays out is primarily taxed ...

and provides an overview of recent and upcoming business highlights. “Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ ...

and provided recent operational highlights. The Company reported $22.4 million in net revenue from sales of XHANCE during the three-month period ended December 31, 2024, an increase of 13% ...

the preliminary nature of the Company’s estimates of the charges and cash expenditures to be incurred in connection with the recent workforce reduction; the Company may not realize the benefits ...

and provides an overview of recent and upcoming business highlights. "Over the last twelve months, Plus has reported very promising safety and efficacy data for our lead drug REYOBIQ administered in ...

The video highlights historical and contemporary challenges, including threats from Russia and China. Vice President Vance's recent visit to Greenland includes military briefings and strengthens ...

Recent Highlights Annual 2024 Operating Results Revenues: Revenues were $56 thousand for the year ended December 31, 2024, compared to $3.2 million for the same period in 2023. Revenues for 2024 ...

today announced financial results for the fourth quarter and full year 2024, as well as corporate and clinical highlights.

2024 and highlighted recent developments. “The financing concluded in October positioned us to focus our clinical development efforts on advancing IkT-001 toward a late-stage clinical trial in ...

An inflection in prescription demand first observed in September 2024 NRx continued in fourth quarter 2024 and extended to TRx. NRx increased 12% from approximately 25,600 in third quarter 2024 to ...